Key result
Cardiac-specific circulating microRNAs show strong promise as stable, accurate diagnostic biomarkers for ACS.
Why the study?
Current cardiac biomarkers for ACS diagnosis have drawbacks including delayed rise and elevation in CKD patients, prompting investigation of cardio-specific miRNAs as novel biomarkers.
Do circulating microRNAs serve as effective and specific biomarkers for the diagnosis of acute coronary syndrome?
Systematic Review
Do circulating microRNAs serve as effective and specific biomarkers for the diagnosis of acute coronary syndrome?
Circulating microRNAs such as miR-1, miR-133a/b, miR-208a/b, and miR-499a show promise as highly specific biomarkers for the early diagnosis of acute coronary syndrome.
May support miRNA panels for early ACS triage; extends single-study data via systematic synthesis.
The severe and acute manifestation of coronary artery disease (CAD) is acute coronary syndrome (ACS); therefore, prompt diagnosis can save lives. Cardiac biomarkers that are accepted to use in evaluating ACS are creatine kinase muscle/brain subtype (CK-MB), cardiac troponin I (CTnI), or cardiac troponin T (CTnT). However, these markers have several drawbacks, such as prolonged time to rise for prompt diagnosis and elevation in patients with chronic kidney diseases (CKD). Lately, potential, novel candidates for cardiac ischemia biomarkers have been developed, one of which is micro-ribonucleic acids (miRNAs). miRNAs are potential due to their remarkable reproducibility and stability. Several miRNAs, such as, miR-1, miR-133a, miR-133b, miR-208a, miR-208b, and miR-499a, greatly rise in concentration in the plasma or serum of patients with acute cardiac ischemia, signifying their cardiac specificity and promising biomarkers in patients with ACS. This systematic review aims to elucidate the role of cardio-specific miRNA in acute myocardial ischemia (AMI) and its relationship with other cardiac biomarkers.
No takes yet. Share an insight, caveat, or question.
Prima Hapsari Wulandari (2021) conducted a systematic review in Acute Coronary Syndrome. Circulating microRNAs (miR-1, miR-133a, miR-133b, miR-208a, miR-208b, miR-499a) vs. Standard cardiac biomarkers (CK-MB, CTnI, CTnT) was evaluated on Role of cardio-specific miRNA in acute myocardial ischemia and relationship with other biomarkers. Circulating microRNAs, such as miR-1, miR-133a/b, miR-208a/b, and miR-499a, are promising biomarkers for acute coronary syndrome due to their cardiac specificity, reproducibility, and stability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: